Pharmacovigilance Experts are key players in the pharmaceutical industry, tasked with ensuring the ongoing safety and effectiveness of medicines. Their main role involves collecting, analyzing, and interpreting data related to adverse drug reactions (ADRs), helping to identify new risks or confirm known ones. These experts monitor both clinical trial data and post-marketing reports to detect safety signals early and prevent harm to patients. They prepare detailed safety reports, manage regulatory submissions, and maintain compliance with international pharmacovigilance regulations such as those from the FDA, EMA, and ICH.
These professionals possess strong analytical, communication, and decision-making skills, which are essential for assessing complex safety data and making informed recommendations. They work closely with regulatory teams, medical affairs, and research and development departments to ensure all safety concerns are addressed appropriately. With the growing volume of real-world data and digital health records, their role is evolving to include advanced data analytics and AI tools. As new therapies—especially biologics and personalized medicines—enter the market, their role becomes even more critical. Pharmacovigilance experts help guide decisions that can lead to label updates, safety warnings, or even product withdrawal when needed. By identifying patterns in adverse event reports and applying medical judgment, they help reduce risks and ensure that the benefits of a drug continue to outweigh its risks. Their work protects both patients and public health on a global scale.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico